Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2517123 | 0.85 | MEN1 (0.62) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1422197 | 0.84 | USP2 (0.65) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL2994061 | 0.83 | GAA (0.63) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL11148867 | 0.83 | TDP1 (0.66) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5453322 | 0.82 | MEN1 (0.58) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL623009 | 0.80 | AGTR1 (0.62) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3568101 | 0.80 | USP2 (0.68) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6302757 | 0.80 | USP2 (0.68) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL184604 | 0.79 | AGTR1 (0.64) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5018821 | 0.78 | USP2 (0.71) | USP2MEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100189685-A1 | Antiviral Drugs for Treatment or Prevention of Dengue Infection | SIGA TECHNOLOGIES, INC. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189685-A1 | Antiviral Drugs for Treatment or Prevention of Dengue Infection | EIF2AK2, HAVCR2, SNRPE | USP2 3743/4885MAPK1 2313/4885MEN1 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.